Home|DSIJArticleDetail

Pharma Penny Stock Under Rs 50: Company Is Establishing A State-Of-The-Art R&D Center In Hyderabad To Enhance Its Capabilities
Pharma Penny Stock Under Rs 50: Company Is Establishing A State-Of-The-Art R&D Center In Hyderabad To Enhance Its Capabilities

Pharma Penny Stock Under Rs 50: Company Is Establishing A State-Of-The-Art R&D Center In Hyderabad To Enhance Its Capabilities

From Rs 43.42 per share (52-week low) to Rs 45.49 per share, the stock is up by 5 per cent.

Kiran Shroff Article rating: 5.0

From Rs 43.42 per share (52-week low) to Rs 45.49 per share, the stock is up by 5 per cent.

Multibagger pharma penny stock under Rs 5 jumps after entering into a Supper stockist agreement with Amneal Healthcare Private Limited
Multibagger pharma penny stock under Rs 5 jumps after entering into a Supper stockist agreement with Amneal Healthcare Private Limited

Multibagger pharma penny stock under Rs 5 jumps after entering into a Supper stockist agreement with Amneal Healthcare Private Limited

The company has a market cap of Rs 223 crore and the stock gave multibagger returns of over 100 per cent from its 52-week low of Rs 1.92 per share.

Kiran Shroff Article rating: 3.6

The company has a market cap of Rs 223 crore and the stock gave multibagger returns of over 100 per cent from its 52-week low of Rs 1.92 per share.

Penny Pharma Stock Under Rs 70 Hit Upper Circuit: Company Fixes Record Date for Bonus Issue – Check the Details Inside
Penny Pharma Stock Under Rs 70 Hit Upper Circuit: Company Fixes Record Date for Bonus Issue – Check the Details Inside

Penny Pharma Stock Under Rs 70 Hit Upper Circuit: Company Fixes Record Date for Bonus Issue – Check the Details Inside

The Board of Directors approved a 2:1 bonus issue (i.e., 2 shares for every 1 share held), subject to members' approval. Here’s the record date.

Abhishek Wani Article rating: 3.4

The Board of Directors approved a 2:1 bonus issue (i.e., 2 shares for every 1 share held), subject to members' approval. Here’s the record date.

 

DSIJ MINDSHARE

Mkt Commentary5-Feb, 2025

Penny Stocks5-Feb, 2025

Personal Finance5-Feb, 2025

Penny Stocks5-Feb, 2025

MF5-Feb, 2025

Knowledge

Personal Finance5-Feb, 2025

MF5-Feb, 2025

Knowledge5-Feb, 2025

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Conditions | Privacy Statement | WhiteList